A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients - Related Studies

A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients

This study has been completed.

Study NCT00001669. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Multiple Sclerosis

2	Additional conditions recognized in this trial
		Sclerosis

3	More general conditions related to this trial
		Autoimmune Diseases
		Autoimmune Diseases of the Nervous System
		Demyelinating Autoimmune Diseases, CNS
		Demyelinating Diseases
		Immune System Diseases
		Nervous System Diseases
		Pathologic Processes

4	Interventions listed in this trial
		rhIGF-1 (CEP-151)

5	Sponsors listed in this trial
		National Institute of Neurological Disorders and Stroke (NINDS)